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NOD2-Associated
Autoinflammatory Disease
(Yao Syndrome) and
HCV Infection With Fatal
Consequences
Interaction Between Genes
and EnvironmentTo the Editor:A utoinflammatory diseases are geneti-cally determined disorders character-
ized by recurrent inflammatory episodes.1,2
In 2011, Yao and coworkers2,3 described
a novel autoinflammatory disease that is
now recognized under the name of NAID
(NOD2-associated autoinflammatory dis-
ease) or Yao syndrome. It is characterized
by periodic fever, dermatitis, polyarthritis,
sicca-like symptoms, and gastrointestinal
involvement. The syndrome appears to be
caused by 2 mutations in the NOD2 gene,
IVS8+158 and Arg702Trp. NOD2 is a typ-
ical pattern-recognition receptor that binds
degradation products from bacteria and
viruses and induces inflammation.4,5 We
have studied a patient with a chronic hep-
atitis C virus (HCV) infection who devel-
oped a systemic inflammatory response
syndrome during treatment of the viral in-
fection with ribavirin and interferon. The
symptoms were typical of Yao syndrome,
and the patient carried the 2 characteristic
NOD2 mutations. Although Yao syndrome
is not a fatal disease,6 our patient developed
progressive liver failure and died 14 years
after onset of the autoinflammation. It is
likely that the viral treatment had triggered
the onset of the autoinflammatory syn-
drome. Thus, an interferon therapy should
be avoided in patients with Yao syndrome.
This is the second report of a patient with
Yao syndrome from a hospital other than
the Cleveland Clinic.7
DESCRIPTION OF THE PATIENT
In 2003, a patient presented at our clinic
because of a systemic inflammatory response
syndrome. It was known that he had an
HCV infection, which was successfully
controlled by treatment with ribavirin and
interferon. However, shortly after start of
the therapy, he began to complain about
fever, night sweat, weight loss, fatigue,
and joint pain. A thorough examinationJCR: Journal of Clinical Rheumatology • Volume
Copyright © 2018 Wolters Kfor infectious, neoplastic, or autoimmune
diseases was negative. Thus, the symptoms
were judged to be of autoinflammatory
origin, and the patient was successfully
treated with prednisone over 1.5 years.
In February 2007, he had a relapse
of the inflammatory syndrome with sicca-
like symptoms, anemia, and nocturnal dys-
pnea. Treatment with the anti-TNF biologic
adalimumab could stabilize the condition
during the following year. Yet in January
2009, he had another relapse, which was
accompanied by dermatitis. Because the
symptoms were characteristic for IL-6 ac-
tivity and because IL6 in serum was ele-
vated, a therapy with the anti–IL6-receptor
antibody tocilizumab was initiated. This
treatment was highly effective; the acute
phase response could be completely controlled
by the antibody. The patient did not show
any symptoms for a period of 5 years and
was able to go traveling and skiing.
Unfortunately, the chronic liver disease
proceeded during this period. Several liver
biopsies were performed, which showed
progression of fibrosis (F3 on the last
biopsy), but Congo red staining for amy-
loidosis was negative. In 2013, the patient
developed a nodular regenerative hyperpla-
sia with portal hypertension. At this time,
all symptoms of the autoinflammatory syn-
drome returned and were unresponsive to
tocilizumab. The patient dramatically lost
weight and required parenteral nutrition.
In May 2017, he developed a Candida sep-
sis and died.
In 2016, when the inflammation could
not anymore be controlled by tocilizumab,
we set out to elucidate the molecular cause
of the autoinflammatory syndrome and per-
formed whole exome sequencing with ge-
nomic DNA from the patient's blood. A
total of 33,034,680 sequence reads were
obtained. Comparison with the reference
genome GRCh37.75 revealed 41,379 poly-
morphisms. Sequence variants that did not
occur in the reference library of humans
with no medical impact (ftp://ftp.ncbi.nlm.
nih.gov/pub/clinvar/vcf_GRCh37/) were fur-
ther filtered for homozygous mutations,
frame shifts, or stop codons. Furthermore,
all genes that had previously been asso-
ciated with autoinflammatory diseases,8
amyloidosis,9 and sarcoidosis10 were in-
cluded. Finally, more than 600 genes were
individually analyzed using the Integrative
Genomics Viewer 2.3.92 (http://www.
broadinstitute.org/igv/). This procedure
led to the identification of 10 sequence var-
iants that were of interest in the context of a
patient with autoinflammatory syndrome00, Number 00, Month 2018
luwer Health, Inc. Unauthorized reproduction oand liver fibrosis (Fig. A). All mutations
were confirmed by Sanger cycle sequencing.
At least 3 of the polymorphisms might
have pathogenic consequences, namely, the
Arg702Trp variant in NOD2, the Met1Val
variant in TLR8, and the Ala25Thr variant
in CST3. Additional sequencing of intron
8 from NOD2 disclosed the pathogenic
IVS8+158 mutation,6 which finally led
to the diagnosis of Yao syndrome. TLR8
is known to occur in 2 alternatively
spliced variants.11 The hemizygous mutation
Met1Val eliminates the start codon of
transcript variant 1 (NM_016610) such
that our patient was able to produce
only transcript variant 2 (NM_138636).
Cell culture experiments suggested that
variant 2 induces significantly stronger
cytokine production than variant 1.11
CST3 codes for the proteinase inhibitor
cystatin C, which is a frequent constituent
of amyloid plaques.12 The homozygous
CST3 mutation of our patient substitutes
Ala-25 by Thr at the signal peptide
cleavage site. This Thr occurs within
the tripeptide sequence Thr-Gly-Ser,
which can function as acceptor site for
O-glycosylation. The mutated protein does
in fact become glycosylated as demonstrated
by tandem mass spectrometry.13 Although
the implications of this modification remain
to be elucidated, the Ala25Thr mutation has
been associated with Alzheimer disease
and macular degeneration.12 Together, the
mutations may explain the autoinflammatory
syndrome of our patient.
The pedigree of the patient's family
(Figs. B–C) suggested that the genetic
predisposition for Yao syndrome was
inherited from the father who died at
58 years as a weak, ailing person. The
wife of our patient was negative for the
potentially pathogenic NOD2 and CST3
mutations, but the son was positive for
all the mutations in NOD2, TLR8, and
CST3. Thus, he must have inherited the
pathogenic NOD2 mutations from his
father, which rules out the possibility of
compound heterozygosity.
DISCUSSION
Yao syndrome is a polygenic disease that
requires a specific trigger.2,3 To our knowl-
edge, this is the first case of Yao syndrome
in the context of HCV infection. Based on
the patient chart, the HCV infection was ac-
quired during a blood transfusion in 1985
and persisted for more than 15 years as
an unnoticed chronic disease. It is likely
that the HCV infection contributed to thewww.jclinrheum.com 1
f this article is prohibited.
FIGURE. Sequence variants of the patient with autoinflammatory syndrome. A, Whole
exome sequencing revealed 10 variants that are of interest in the context of the disorder of
the patient. Sanger sequencing of intron 8 from NOD2 revealed the potentially pathogenic
variant IVS8+158 that finally led to the diagnosis of Yao syndrome. B, Pedigree of the
patient's family. Overt Yao syndrome is observed only with the index patient (5). His father
(1) was known as a weak, ailing person, who died at the age of 58 years. C, Sequence
variants identified in the family. The index patient (5) and his son (10) carry the NOD2
mutations Arg702Trp and IVS8+158, the TLR8mutation, as well as the CST3mutation.
Letter to the Editor JCR: Journal of Clinical Rheumatology • Volume 00, Number 00, Month 2018outbreak of Yao syndrome. However,
the actual trigger might have been the
ribavirin/interferon therapy, because this
therapy immediately preceded the outbreak
of the autoinflammatory symptoms. This
fact is of particular interest because inter-
feron has been associated with several
newly discovered autoinflammatory disor-
ders,14 implying that interferon should be
avoided in patients with Yao syndrome.
In fact, our patient carried 2 common
polymorphisms in IFIH1 (Fig. A), which
have been shown to augment the levels of
interferon and to increase resistance to
viral infection, but at the cost of a propensity
for interferon-mediated autoinflammation.14
Although the virus had been completely
eliminated as verified on multiple occasions,
the patient developed a chronic hepatopathy
after completion of the HCV therapy. This
suggests that the Yao syndrome might
have been involved in the onset of the
fibrosing liver disease. Thus, it might have
been the fatal coincidence of HCV infection2 www.jclinrheum.com
Copyright © 2018 Wolters Kluand Yao syndrome that finally led to liver
failure and the death of our patient.
Our thorough genetic analysis leads to
several take-home messages:
• A genetic predisposition for an auto-
inflammatory disease may remain si-
lent until an exogenous trigger activates
the pathway.
• Autoinflammatory diseases are often
polygenetic, and several mutations may
act in concert.
• An anticytokine therapy to neutralize
IL-6 may result in complete clinical
remission. However, it bears the risk
of progression of a subclinical fibrosing
liver disease.Beat Trueb, PhD
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